Company Profile

We bring products to market sooner


We believe that our purpose is to assist our sponsors in bringing safe and effective pharmaceutical products to market.


We tailor our services to accommodate our sponsors approaches by offering integrated services in a program solution or stand-alone solution.


We understand the complex nature of drug development with its scientific challenges, regulatory hurdles and commercial pressures.


We recognize that our sponsors have the choice to progress with development in-house or to outsource to us or to others.


We respect our sponsor’s requirement for absolute confidentially – trust that cannot be compromised by partners in a very competitive industry.




Entrance in formulation development, NUVISAN has been awarded by NESTLÉ SKIN HEALTH to take over parts of the GALDERMA R&D activities at Sophia-Antipolis, France. The is since its opening in 2006 the world’s largest research center focused on medical solutions for the skin. The partnering with GALDERMA will strengthen three of NUVISAN’S key service lines in Bioanalysis, Clinical Trial Supplies and Pharmaceutical Analytics.

Establishment of Nuvisan Inc., a subsidiary of NUVISAN GmbH, in Boston, Massachusetts USA.

Entry into new business field through the acquisition and integration of a non-clinical research and development site in Grafing from the long-standing partner Merck KGaA. With the addition of non-clinical DMPK services, NUVISAN enters the next phase of its realignment as a preclinical and clinical contract research organization to support the global pharmaceutical industry.

Expansion to Waltrop Germany through takeover of the Essex Pharma research institute from the MSD Group. Part of this agreement was the transfer of all employees to strengthen and maintain the pharmaceutical testing business through the integration of large-scale stability programs and services, and the opportunity to expand into specific areas of pharmaceutical analysis of hormones, polymers and large molecules.

Established as NUVISAN GmbH following the sale and divestiture of the AAIPharma family of companies to new owners.

Renamed AAIPharma Deutschland to coincide with the renaming of AAI International to AAIPharma in the USA.

Acquired by AAI International (Wilmington, NC) a multifunctional contract research organization headquartered in the USA and providing GCP, GLP, and GMP related services to the pharmaceutical industry in support of early to late stage product development. Through this acquisition AAI International established a European presence and in addition expanded its service offerings in GxP related activities.

Founded as LAB GmbH, as one of the first German based contract research organization serving the clinical development needs of the pharmaceutical industry. The company quickly developed into a full service provider in the early clinical phase and thus forms the basis for today's organizational structure.


Business Development
Please send us an Email!


Bio Europe Spring
25.03 - 27.03.2019
Vienna / Austria

Euro Biosimilars
12th European Biosimilars Congress
15.04 - 16.04.2019
Berlin / Germany

Swiss Biotech
Swiss Biotech Day 2018
Basel / Switzerland